Broker Center sponsored links

India's Ranbaxy gets US okay for antihistamine tablets

Thu Apr 12, 2007 10:38am EDT
 
Email | Print | | Reprints | Single Page
[-] Text [+]

April 12 (Reuters) - India's Ranbaxy Laboratories Ltd. (RANB.BO: Quote, Profile, Research, Stock Buzz) said it got U.S. Food and Drug Administration approval to market Loratadine antihistamine tablets.

Ranbaxy's Loratadine tablets are bioequivalent to Claritin Reditabs of Schering Plough Healthcare Products, the U.S. over-the-counter and consumer products business unit of Schering-Plough Corp. (SGP.N: Quote, Profile, Research, Stock Buzz). (Reporting by Rakesh Sharma in Bangalore)

 

Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.

Have a correction to this article? Email the editors

Featured Broker sponsored link

Editor's Choice

  • Pictures
  • Video
  • Articles
Photo

A selection of our best photos from the past 24 hours.  View Slideshow 

Most Popular on Reuters

  • Articles
  • Video
  • Recommended